Mazdutide 化学特性,用途語,生産方法
説明
Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss of up to 6.4% at doses up to 6 mg in Chinese adults with overweight or obesity. It is the first GLP-1R/GCGR dual agonist to succeed in Phase 3 trials. As mazdutide's first registrational trial for weight management, the results of GLORY-1 not only further confirm the efficacy and safety of the mazdutide in a large population but also provide high-quality clinical evidence of long-term pharmacotherapy weight management specifically for the Chinese population with overweight or obesity[1].
副作用
Compared to placebo, it was also associated with reductions in fasting plasma glucose and HbA1c among patients with diabetes. Mazdutide was associated with more side effects, primarily gastrointestinal-related disorders, such as decreased appetite, nausea, vomiting and diarrhea. Moreover, all participants on Mazdutide experienced an increase in heart rates. However, these side effects were transient and mild to moderate in severity, and no participant discontinued treatment due to the side effects[2].
Mazdutide 上流と下流の製品情報
原材料
準備製品